<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03498287</url>
  </required_header>
  <id_info>
    <org_study_id>PPS-CTS-SBIR2</org_study_id>
    <nct_id>NCT03498287</nct_id>
  </id_info>
  <brief_title>Non-invasive CTS Device Clinical Trial</brief_title>
  <official_title>Randomized Controlled Clinical Trial of Non-invasive Device to Alleviate Carpal Tunnel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pressure Profile Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mission Pain and Spine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pressure Profile Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sham-controlled, multi-center and remote patient-centered randomized controlled clinical
      trial to investigate the efficacy of a novel non-invasive, unobtrusive study device in
      reducing symptoms of carpal tunnel syndrome (CTS). Daily wear of the study device is expected
      to significantly reduce symptom severity (evaluated by the Boston Carpal Tunnel
      Questionnaire) in mild to severe CTS-diagnosed patients. Subjects are randomized into the
      active device group or sham group for 8 weeks, then followed for 12 weeks post-treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that daily wear of the study device will result in significant
      improvements in patient-reported symptom severity. It is also hypothesized that the effects
      from active study device treatment will be significantly greater than effects from sham
      treatment. In both cases, it is hypothesized that improvements will be sustained
      post-treatment.

      This study is designed as a randomized, double-blind, sham-controlled, two-arm trial
      consisting of an eight-week treatment period (active study device or sham), followed by one
      required follow-up four weeks later (at week 12).

      There are two study groups: the active device group receiving the active study device and the
      sham group receiving a non-active sham device. Subjects will be informed that they have a
      50:50 chance of receiving treatment or a sham. They will also be informed that if they
      receive sham device, they will be offered the active device 4 weeks into the post-treatment
      period. However, all subjects will not know what treatment they are on until the conclusion
      of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Actual">April 21, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BCTQ SSS at 8 Weeks vs Baseline</measure>
    <time_frame>baseline and 8 weeks post-Baseline</time_frame>
    <description>The Symptom Severity Scale (SSS) of the Boston Carpal Tunnel Questionnaire (BCTQ) is an 11-question patient-administered survey that rates the severity of the patient's carpal tunnel syndrome-specific symptoms on a scale of 1 (no symptoms) to 5 (worst symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCTQ SSS</measure>
    <time_frame>8-weeks post-Baseline and 12 weeks post-Baseline</time_frame>
    <description>The Symptom Severity Scale (SSS) of the Boston Carpal Tunnel Questionnaire (BCTQ) is an 11-question patient-administered survey that rates the severity of the patient's carpal tunnel syndrome-specific symptoms on a scale of 1 (no symptoms) to 5 (worst symptoms).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <arm_group>
    <arm_group_label>Study Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Small, non-invasive, stiff patch for the wrist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Device</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Study Device</intervention_name>
    <description>Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).</description>
    <arm_group_label>Study Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Device</intervention_name>
    <description>Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). *Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.</description>
    <arm_group_label>Sham Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinically diagnosed with mild to severe carpal tunnel syndrome (CTS)

          2. CTS diagnosis confirmed by a nerve conduction study (NCS) performed within the past 24
             months OR at enrollment/baseline visit

               1. CTS severity determined via AANEM criteria 13

               2. Bilateral CTS accepted (worse wrist via NCS and/or BCTQ is designated as the
                  study wrist)

          3. BCTQ SSS &gt; 2

          4. Reliable access to and ability to use Internet, Wi-Fi, or mobile data through
             computers, mobile devices, laptops, and/or tablets

          5. Willing to abstain from any other treatment or therapies for CTS throughout the study

          6. Ability to read and write English, or has a reliable person to assist with reading and
             writing English

        Exclusion Criteria:

          1. Other upper extremity neuropathies (e.g., epicondylitis, radial nerve neuropathies,
             ulnar nerve neuropathies)

          2. Double crush syndrome

          3. Cervical stenosis

          4. Brachial plexopathy

          5. Wrist fractures or cysts

          6. Prior wrist surgeries, especially carpal tunnel release surgery

          7. Injection of corticosteroid/cortisone into the wrist or hand within the past 6 months

          8. Thyroid disease

          9. Rheumatoid arthritis

         10. Diabetes

         11. Systemic diseases

         12. Connective tissue diseases

         13. Fibromyalgia or chronic pain syndrome

         14. Diabetic neuropathy

         15. BMI &gt; 40

         16. Participation in other research studies or clinical trials currently or within the
             past 2 weeks.

        To assess eligibility, visit: carpaltunneltrial.com
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Son, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pressure Profile Systems</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mission Pain &amp; Spine</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bay Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic (Lerner Research Institute)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aanem.org/Practice/Guidelines-and-Performance-Measures</url>
    <description>Practice Parameter for Electrodiagnostic Studies in Carpal Tunnel Syndrome: Summary Statement.</description>
  </link>
  <reference>
    <citation>Leite JC, Jerosch-Herold C, Song F. A systematic review of the psychometric properties of the Boston Carpal Tunnel Questionnaire. BMC Musculoskelet Disord. 2006 Oct 20;7:78. Review.</citation>
    <PMID>17054773</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 8, 2018</study_first_submitted>
  <study_first_submitted_qc>April 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <results_first_submitted>June 8, 2020</results_first_submitted>
  <results_first_submitted_qc>June 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2020</results_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carpal tunnel syndrome</keyword>
  <keyword>carpal tunnel</keyword>
  <keyword>CTS</keyword>
  <keyword>musculoskeletal disorder</keyword>
  <keyword>peripheral neuropathy</keyword>
  <keyword>repetitive stress injury</keyword>
  <keyword>non-invasive device</keyword>
  <keyword>non-significant risk</keyword>
  <keyword>medical device</keyword>
  <keyword>wrist pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03498287/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Device</title>
          <description>Small, non-invasive, orthodontic arch with adhesive applied to the wrist
Study Device: Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). (1 wrist per participant)</description>
        </group>
        <group group_id="P2">
          <title>Sham Device</title>
          <description>Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
Sham Device: Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). (1 wrist per participant)
*Note: participants in the sham group were given the real study device at the end of the Post-Treatment/Follow-up Phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Device</title>
          <description>Small, non-invasive, orthodontic arch with adhesive applied to the wrist
Study Device: Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).</description>
        </group>
        <group group_id="B2">
          <title>Sham Device</title>
          <description>Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
Sham Device: Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). *Note: participants in the sham group were given the real study device at the end of the Post-Treatment/Follow-up Phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="11.7"/>
                    <measurement group_id="B2" value="48.6" spread="9.9"/>
                    <measurement group_id="B3" value="48.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decline to Answer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Boston Carpal Tunnel Questionnaire (BCTQ) Symptom Severity Score (SSS)</title>
          <description>enrollment/baseline symptom severity score on the 1-5 Likert scale with 1 being no symptoms and 5 being worst symptoms</description>
          <population>80 per-protocol patients analyzed vs total number enrolled</population>
          <units>units on a 1-5 Likert scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.78" spread=".58"/>
                    <measurement group_id="B2" value="2.96" spread=".42"/>
                    <measurement group_id="B3" value="2.87" spread=".52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BCTQ Functional Severity Score (FSS)</title>
          <description>enrollment/baseline functional severity score on the 1-5 Likert scale with 1 being no symptoms and 5 being worst symptoms</description>
          <population>80 per-protocol patients analyzed vs total number enrolled</population>
          <units>units on a 1-5 Likert scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.21" spread=".72"/>
                    <measurement group_id="B2" value="2.39" spread=".70"/>
                    <measurement group_id="B3" value="2.30" spread=".71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BCTQ SSS at 8 Weeks vs Baseline</title>
        <description>The Symptom Severity Scale (SSS) of the Boston Carpal Tunnel Questionnaire (BCTQ) is an 11-question patient-administered survey that rates the severity of the patient's carpal tunnel syndrome-specific symptoms on a scale of 1 (no symptoms) to 5 (worst symptoms).</description>
        <time_frame>baseline and 8 weeks post-Baseline</time_frame>
        <population>Per-protocol population (patients that completed at least up to the first post-treatment follow-up (Week 12))</population>
        <group_list>
          <group group_id="O1">
            <title>Study Device</title>
            <description>Small, non-invasive, orthodontic arch with adhesive applied to the wrist
Study Device: Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Sham Device</title>
            <description>Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
Sham Device: Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). *Note: participants in the sham group were given the real study device at the end of the Post-Treatment/Follow-up Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>BCTQ SSS at 8 Weeks vs Baseline</title>
          <description>The Symptom Severity Scale (SSS) of the Boston Carpal Tunnel Questionnaire (BCTQ) is an 11-question patient-administered survey that rates the severity of the patient's carpal tunnel syndrome-specific symptoms on a scale of 1 (no symptoms) to 5 (worst symptoms).</description>
          <population>Per-protocol population (patients that completed at least up to the first post-treatment follow-up (Week 12))</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average SSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" spread=".65"/>
                    <measurement group_id="O2" value="2.32" spread=".70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Change in SSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.69"/>
                    <measurement group_id="O2" value="-0.64" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BCTQ SSS</title>
        <description>The Symptom Severity Scale (SSS) of the Boston Carpal Tunnel Questionnaire (BCTQ) is an 11-question patient-administered survey that rates the severity of the patient's carpal tunnel syndrome-specific symptoms on a scale of 1 (no symptoms) to 5 (worst symptoms).</description>
        <time_frame>8-weeks post-Baseline and 12 weeks post-Baseline</time_frame>
        <population>Per-protocol population (patients that completed at least up to the first post-treatment follow-up (Week 12))</population>
        <group_list>
          <group group_id="O1">
            <title>Study Device</title>
            <description>Small, non-invasive, orthodontic arch with adhesive applied to the wrist
Study Device: Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Sham Device</title>
            <description>Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
Sham Device: Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). *Note: participants in the sham group were given the real study device at the end of the Post-Treatment/Follow-up Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>BCTQ SSS</title>
          <description>The Symptom Severity Scale (SSS) of the Boston Carpal Tunnel Questionnaire (BCTQ) is an 11-question patient-administered survey that rates the severity of the patient's carpal tunnel syndrome-specific symptoms on a scale of 1 (no symptoms) to 5 (worst symptoms).</description>
          <population>Per-protocol population (patients that completed at least up to the first post-treatment follow-up (Week 12))</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average SSS @12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread=".70"/>
                    <measurement group_id="O2" value="2.44" spread=".68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Change in SSS between 12 and 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.48"/>
                    <measurement group_id="O2" value="0.12" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patient participation duration: 5-6 months</time_frame>
      <desc>Device is a non-invasive externally-worn orthotic made of hypoallergenic materials and does not introduce any medications, chemicals, biologics, or electromagnetic energy into the body. Only expected adverse events are related to skin reaction, rash, allergy, discomfort from device wear, and progression of carpal tunnel syndrome.</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Device</title>
          <description>Small, non-invasive, orthodontic arch with adhesive applied to the wrist
Study Device: Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).</description>
        </group>
        <group group_id="E2">
          <title>Sham Device</title>
          <description>Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
Sham Device: Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). *Note: participants in the sham group were given the real study device at the end of the Post-Treatment/Follow-up Phase.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rash, redness, or sore under study device</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Authorship will reflect joint cooperation between PPS and participating PI(s). Authorship responsibilities should be established prior to the writing of any manuscript.
No individual publications are allowed unless agreed upon, reviewed, and approved by the Sponsor before submission and/or publication. No individual publications are allowed prior to the completion of a final report for the study.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sham device was not thoroughly tested before the trial. Post-trial testing suggest some mechanical effect that could have influenced the sham group response. Early termination of enrollment reduced the power of the statistical analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trials Manager</name_or_title>
      <organization>Pressure Profile Systems</organization>
      <phone>310.641.8100</phone>
      <email>research@wrist-aid.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

